Core Viewpoint - Gilead Sciences-B (01672) saw a stock increase of over 7%, currently trading at 10.11 HKD, following its inclusion in the MSCI Global Small Cap Index, effective after market close on November 24 [1] Group 1: Stock Performance - Gilead Sciences-B's stock rose by 6.98%, with a trading volume of 21.57 million HKD [1] Group 2: MSCI Inclusion - On November 6, MSCI announced the results of its November index review, which included Gilead Sciences-B in the MSCI Global Small Cap Index [1] Group 3: Clinical Research Updates - Gilead Sciences-B presented multiple reports at the 2025 ObesityWeek in Atlanta, Georgia, including a complete analysis of the ASC30 oral tablet Phase Ib study [1] - The ASC30 oral tablet study showed an average weight loss of up to 6.5% after placebo adjustment, demonstrating good safety and tolerability with only mild to moderate gastrointestinal adverse events [1] - The apparent half-lives of the ASC30 injection were 46 days and 75 days, supporting monthly and quarterly dosing regimens [1]
港股异动 | 歌礼制药-B(01672)涨超7% 公司获纳入MSCI全球小盘股指数 ASC30减重效果显著